印度仿制药巨头盯上国产“替尼”,恒瑞们准备好了吗?

湾财ND
Jul 23

2026年7月10日,国家药监局一纸批件打破沉寂——印度仿制药巨头瑞迪博士实验室(Dr. Reddy's,简称DRL)在华合资公司“昆山龙灯瑞迪”,拿下了贝达药业埃克替尼(凯美纳)的首仿获批。几乎同时,这家以极致成本策略著称的“世界药厂”,启动了正大天晴“安罗替尼”的生物等效性预试验。  这不仅意味着中国首个完全自主知识产权的小分子靶向抗癌药结束了15年的原研独占,更释放了一个强烈信号:中国初代...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10